Recognizing the Symptoms of APDS2
At a Glance
APDS2 symptoms vary widely, but often begin with recurrent ear, sinus, or chest infections in childhood. Other possible signs include persistent swollen lymph nodes, an enlarged spleen, slower growth, developmental delays, digestive inflammation, autoimmunity, and permanent airway damage.
APDS2 is a complex condition that can look very different from one person to the next. Because it affects the “master controller” of certain immune cells, it causes a wide range of symptoms that can affect almost any part of the body [1]. While some people with the genetic change have very few symptoms (incomplete penetrance), others may experience frequent and serious health challenges starting in early childhood [2][3].
The Early Pattern: Infections and Swelling
For most children with APDS2, the first sign that something is wrong is a pattern of frequent, “back-to-back” infections. In one study of a 36-patient APDS2 cohort, every single person (100%) experienced recurrent upper respiratory tract infections, such as ear and sinus infections [4]. (Note: precise frequencies describe specific study cohorts and are not individual prognoses.)
- Respiratory Infections: Beyond simple colds, about 71% of patients in that cohort developed pneumonitis (inflammation or infection of the lung tissue) [4].
- Swollen Lymph Nodes: About 75% of patients had lymphadenopathy—chronically swollen lymph nodes that may stay enlarged even when the person isn’t sick [4].
- Enlarged Spleen: Roughly 43% of patients developed splenomegaly, or an enlarged spleen [4]. This can sometimes cause a feeling of fullness in the belly or mild discomfort.
Growth and Development
Unlike some other immune disorders, APDS2 often affects how a child grows and develops. This is because the PIK3R1 gene is active in many types of cells, not just the immune system [5].
- Growth Findings: Nearly half (45%) of patients in the 36-patient cohort experienced slower-than-normal growth or short stature [4]. In some cases, this can be a very prominent feature of the disease [6].
- Neurodevelopment: About 31% of patients in that cohort experienced mild neurodevelopmental delays, which can affect how they learn or reach certain milestones [4].
Chronic and Progressive Symptoms
As the disease progresses, other parts of the body may become involved. These are often chronic issues that require ongoing management.
- Digestive Issues: Approximately 24% of patients in the cohort experienced chronic diarrhea or bowel inflammation [4]. This is often caused by the immune system overreacting within the lining of the gut [7].
- Autoimmunity: In about 17% of cases, the immune system begins to attack the body’s own healthy cells [4]. This can lead to autoimmune hemolytic anemia (where the body destroys its own red blood cells) or other inflammatory conditions like lupus-like symptoms [8].
- Airway Damage: Over time, the cycle of repeated lung infections can lead to bronchiectasis—a permanent scarring and widening of the airways that makes it even harder to clear mucus and infections [4][9].
Variability and Progress
It is important to remember that APDS2 is highly variable. Even within the same family, one person might have severe lung issues while another might have only mild symptoms or none at all [2][10].
While researchers have noted common patterns—such as the disease often starting with respiratory infections in early childhood, followed by the development of swollen lymph nodes, and potentially gastrointestinal or autoimmune issues later on—this is not a fixed trajectory [11][7]. Manifestations can occur in different orders, present in adulthood, or remain mild. Having this diagnosis now allows your medical team to monitor these specific areas and intervene based on your unique symptoms.
Common questions in this guide
What are the earliest symptoms of APDS2?
Can APDS2 affect a child’s growth and development?
Why can APDS2 cause swollen lymph nodes or an enlarged spleen?
Can repeated APDS2 infections damage the lungs?
Can APDS2 cause digestive or autoimmune problems?
Do APDS2 symptoms follow the same pattern in everyone?
Get notified when new evidence is published on immunodeficiency 132b.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.
IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ
Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.
PMID: 39679264 - 2
Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.
Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.
Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.
PMID: 35789397 - 3
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME, Wolkewitz M, Schwab C, et al.
The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.
PMID: 37390899 - 4
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134 - 5
Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Moreno-Corona N, Chentout L, Poggi L, et al.
Frontiers in pediatrics 2021; (9()):688022 doi:10.3389/fped.2021.688022.
PMID: 34249818 - 6
Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P, Lorenz M, Cura Daball P, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2016; (27(6)):640-4 doi:10.1111/pai.12585.
PMID: 27116393 - 7
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784 - 8
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.
Conti F, Catelli A, Cifaldi C, et al.
Frontiers in pediatrics 2021; (9()):702546 doi:10.3389/fped.2021.702546.
PMID: 34307262 - 9
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM, Chandra A
Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.
PMID: 29556229 - 10
Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
Hauck F, Magg T, Krolo A, et al.
Klinische Padiatrie 2017; (229(3)):113-117 doi:10.1055/s-0043-104218.
PMID: 28561224 - 11
Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.
Büsch K, Memmott HL, McLaughlin HM, et al.
Advances in therapy 2025; (42(2)):752-771 doi:10.1007/s12325-024-03066-7.
PMID: 39636570
This page is for informational purposes only and does not constitute medical advice. A clinical immunologist and the rest of your healthcare team should interpret APDS2 symptoms and monitoring needs for your specific situation.